Watts GF - Search Results

1

PCSK9 inhibitors - mechanisms of action.

Page MM, Watts GF. Page MM, et al. Among authors: watts gf. Aust Prescr. 2016 Oct;39(5):164-167. doi: 10.18773/austprescr.2016.060. Epub 2016 Oct 1. Aust Prescr. 2016. PMID: 27789927 Free PMC article. Review. No abstract available.

2

Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children.

Page MM, Bell DA, Hooper AJ, Watts GF, Burnett JR. Page MM, et al. Among authors: watts gf. Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):387-403. doi: 10.1016/j.beem.2013.10.004. Epub 2013 Oct 26. Best Pract Res Clin Endocrinol Metab. 2014. PMID: 24840266 Review.

3

Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.

Page MM, Watts GF. Page MM, et al. Among authors: watts gf. Expert Opin Emerg Drugs. 2015 Jun;20(2):299-312. doi: 10.1517/14728214.2015.1035709. Epub 2015 Apr 10. Expert Opin Emerg Drugs. 2015. PMID: 25861882 Review.

4

Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

Page MM, Stefanutti C, Sniderman A, Watts GF. Page MM, et al. Among authors: watts gf. Clin Sci (Lond). 2015 Jul;129(1):63-79. doi: 10.1042/CS20140755. Clin Sci (Lond). 2015. PMID: 25881720 Review.

5

Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.

Page MM, Watts GF. Page MM, et al. Among authors: watts gf. Expert Opin Drug Metab Toxicol. 2015;11(9):1505-15. doi: 10.1517/17425255.2015.1073712. Expert Opin Drug Metab Toxicol. 2015. PMID: 26293511 Review.

6

Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country.

Khoo KL, Page MM, Liew YM, Defesche JC, Watts GF. Khoo KL, et al. Among authors: watts gf. J Clin Lipidol. 2016 Sep-Oct;10(5):1188-94. doi: 10.1016/j.jacl.2016.05.006. Epub 2016 May 13. J Clin Lipidol. 2016. PMID: 27678436

7

PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.

Page MM, Watts GF. Page MM, et al. Among authors: watts gf. Diabetes Obes Metab. 2018 Feb;20(2):270-282. doi: 10.1111/dom.13070. Epub 2017 Aug 30. Diabetes Obes Metab. 2018. PMID: 28736830 Review.

8

PCSK9 inhibition 2018: riding a new wave of coronary prevention.

Ward NC, Page MM, Watts GF. Ward NC, et al. Among authors: watts gf. Clin Sci (Lond). 2019 Jan 22;133(2):205-224. doi: 10.1042/CS20171300. Print 2019 Jan 31. Clin Sci (Lond). 2019. PMID: 30670671 Review.

9

Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.

Ward NC, Page MM, Watts GF. Ward NC, et al. Among authors: watts gf. Diabetes Obes Metab. 2019 Apr;21 Suppl 1:52-62. doi: 10.1111/dom.13637. Diabetes Obes Metab. 2019. PMID: 31002454 Review.

10

Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?

Page MM, Bell DA, Watts GF. Page MM, et al. Among authors: watts gf. Clin Genet. 2020 Apr;97(4):543-555. doi: 10.1111/cge.13685. Epub 2019 Dec 27. Clin Genet. 2020. PMID: 31833051 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

900 results

Search Page

Filters